Novo Nordisk (NVO) has ended its study of Ozempic’s impact on kidney failure in diabetes patients almost a year ahead of schedule due to strong…
October 12, 2023
Novo Nordisk (NVO) has ended its study of Ozempic’s impact on kidney failure in diabetes patients almost a year ahead of schedule due to strong…